Boston Therapeutics Appoints Three to Management Positions

Boston Therapeutics Appoints Three to Management Positions 
Company Appoints Edward Shea as VP Business Development, Tina M.
Gagnon as Consulting Director of Finance, and Yael T. Bobruff, Ph.D.
as Clinical Affairs Manager 
MANCHESTER, NH -- (Marketwired) -- 12/10/13 --  Boston Therapeutics,
Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an
innovative developer of drugs that address diabetes using complex
carbohydrate chemistry, has appointed Edward Shea as Vice President
Business Development, Tina M. Gagnon as Consulting Director of
Finance, and Yael T. Bobruff, Ph.D. as Clinical Affairs Manager,
effective immediately. 
David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics,
said, "As Boston Therapeutics enters the next phase of its growth, it
is imperative that we attract top talent to help us advance and
commercialize our drug development programs. Ed Shea and Tina
Gagnon's business and finance backgrounds, and Dr. Bobruff's
expertise in biology and research significantly strengthen our
management team. I am pleased they have decided to join our Company
and I look forward to working with them in the months and years
ahead." 
Mr. Shea brings 25 years of biopharmaceutical experience in
commercial development, marketing and sales, having most recently
served as Sr. Eastern Area Sales Director at ViroPharma, Inc. Mr.
Shea's diverse experience includes more than 15 years of business
development, marketing and sales leadership positions with
GlaxoSmithKline and Salix Pharmaceuticals, as well as business
development experience with two start up biopharmaceutical companies,
ViroPharma and Critical Therapeutics. He holds a B.S. in
Business/Marketing and an M.B.A. from Salve Regina University in
Newport, RI. 
Ms. Gagnon has more than 20 years of experience in finance. Most
recently she served as Corporate Controller at Micronetics, Inc.
(NASDAQ: NOIZ), where she oversaw a staff responsible for accounts
receivable, accounts payable, inventory management and other
activities. Prior to this, she was Controller at Amherst
Technologies, LLC; Assistant Controller of Fruit of the Loom's Sports
& Licensing Division; and Senior Corporate Auditor at Standex
International Corp. She holds a B.S. in accountancy from Bentley
College. 
Dr. Bobruff was most recently a postdoctoral researcher in the
Department of Systems Biology at Harvard University Medical School in
Boston, where she studied the genetic processes and mechanisms
contributing to the evolution of host-pathogen interactions. She
earned a B.Sc. in biology from the Hebrew University of Jerusalem and
a M.Sc. in civil and environmental engineering and a Ph.D. in
biological science from Stanford University. 
About Boston Therapeutics, Inc. 
Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE)
is an innovator in designing drugs using complex carbohydrate
chemistry. The Company's product pipeline is focused on developing
and commercializing therapeutic molecules that address Type 2
diabetes, including: PAZ320, a non-systemic chewable therapeutic
compound designed to reduce post-meal glucose elevation, and IPOXYN,
an injectable anti-necrosis drug specifically designed to treat lower
limb ischemia associated with diabetes. More information is available
at www.bostonti.com. 
Forward Looking Statements  
This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements relate to
future events or future financial performance, and use words such as
"may," "estimate," "could," "expect" and others. They are based on
our current expectations and are subject to factors and uncertainties
which could cause actual results to differ materially from those
described in the statements. Factors that could cause our actual
performance to differ materially from those discussed in the
forward-looking statements include, among others, that our plans,
expectations and goals regarding the clinical trials are subject to
factors beyond our control and provide no assurance of FDA approval
of our drug development plans. Our clinical trials may not produce
positive results in a timely fashion, if at all, and any necessary
changes during the course of the trial could prove time consuming and
costly. We may have difficulty in enrolling candidates for testing,
which would affect our estimates regarding timing, and we may not be
able to achieve the desired results. Any significant delays or
unanticipated costs in the trials could delay obtaining meaningful
results from Phase II and/or preparing for Phase III with the current
cash on hand.  
Upon receipt of FDA approval, we may face competition with other
drugs and treatments that are currently approved or those that are
currently in development, which could have an adverse effect on our
ability to achieve revenues from this proposed indication. Plans
regarding development, approval and marketing of any of our drugs,
including PAZ320, are subject to change at any time based on the
changing needs of our company as determined by management and
regulatory agencies. To date, we have incurred operating losses since
our inception, and our ability to successfully develop and market
drugs may be affected by our ability to manage costs and finance our
continuing operations. For a discussion of additional factors
affecting our business, see our Annual Report on Form 10-K for the
year ended December 31, 2012, and our subsequent filings with the
SEC. You should not place undue reliance on forward-looking
statements. Although subsequent events may cause our views to change,
we disclaim any obligation to update forward-looking statements. 
Contact: 
Boston Therapeutics, Inc.
Anthony Squeglia
Chief Financial Officer 
Phone: 603-935-9799
Email: anthony.squeglia@bostonti.com 
www.bostonti.com 
 
 
Press spacebar to pause and continue. Press esc to stop.